# Sharon G. Adler

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sharon-g-adler/

## Facts

| Field | Value |
| --- | --- |
| Citations | 21,443 |
| Field | Chronic Kidney Disease and Diabetes |
| h-index | 65 |
| i10-index | 137 |
| Last Known Institution | UCLA Medical Center |
| OpenAlex ID | https://openalex.org/A5058716877 |
| ORCID iD | https://orcid.org/0000-0002-0247-3878 |
| Works | 247 |

## Researcher papers

Showing 12 of 15.

- [Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)](https://scholariq.org/papers/guidelines-for-the-use-and-interpretation-of-assays-for-monitoring-autophagy-3rd/)
- [KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/kdigo-2021-clinical-practice-guideline-for-the-management-of-glomerular-diseases/)
- [Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases](https://scholariq.org/papers/executive-summary-of-the-kdigo-2021-guideline-for-the-management-of-glomerular/)
- [MYH9 is associated with nondiabetic end-stage renal disease in African Americans](https://scholariq.org/papers/myh9-is-associated-with-nondiabetic-end-stage-renal-disease-in-african-americans/)
- [Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy](https://scholariq.org/papers/randomized-trial-of-an-inhibitor-of-formation-of-advanced-glycation-end-products/)
- [Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach](https://scholariq.org/papers/design-of-the-nephrotic-syndrome-study-network-neptune-to-evaluate-primary/)
- [JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial](https://scholariq.org/papers/jak1-jak2-inhibition-by-baricitinib-in-diabetic-kidney-disease-results-from-a/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-1-conclusions-from-a-kidney/)
- [Phase 1 Study of Anti-CTGF Monoclonal Antibody in Patients with Diabetes and Microalbuminuria](https://scholariq.org/papers/phase-1-study-of-anti-ctgf-monoclonal-antibody-in-patients-with-diabetes-and/)
- [Development and evaluation of deep learning–based segmentation of histologic structures in the kidney cortex with multiple histologic stains](https://scholariq.org/papers/development-and-evaluation-of-deep-learning-based-segmentation-of-histologic/)
- [Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-2-conclusions-from-a-kidney/)

## Researcher topics

- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Genetic Associations and Epidemiology](https://scholariq.org/topics/genetic-associations-and-epidemiology/)
- [Dialysis and Renal Disease Management](https://scholariq.org/topics/dialysis-and-renal-disease-management/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions-2/)

## Researcher university

- [UCLA Medical Center](https://scholariq.org/institutions/ucla-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.